Stoke Therapeutics/$STOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Ticker
$STOK
Sector
Primary listing
Employees
170
Headquarters
Website
STOK Metrics
BasicAdvanced
$2B
-
-$0.12
1.19
-
Price and volume
Market cap
$2B
Beta
1.19
52-week high
$40.22
52-week low
$5.35
Average daily volume
906K
Financial strength
Current ratio
5.282
Quick ratio
5.055
Long term debt to equity
0.324
Total debt to equity
1.177
Interest coverage (TTM)
-2,287.78%
Profitability
EBITDA (TTM)
-18.82
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3.73%
Operating margin (TTM)
-11.16%
Revenue per employee (TTM)
$1,080,000
Management effectiveness
Return on assets (TTM)
-3.73%
Return on equity (TTM)
-2.37%
Valuation
Price to revenue (TTM)
10.821
Price to book
5.63
Price to tangible book (TTM)
5.63
Price to free cash flow (TTM)
44.433
Free cash flow yield (TTM)
2.25%
Free cash flow per share (TTM)
0.758
Growth
Revenue change (TTM)
404.50%
Earnings per share change (TTM)
-92.94%
3-year revenue growth (CAGR)
145.89%
3-year earnings per share growth (CAGR)
-64.50%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
STOK News
AllArticlesVideos
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire·1 week ago
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Business Wire·3 weeks ago
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stoke Therapeutics stock?
Stoke Therapeutics (STOK) has a market cap of $2B as of March 27, 2026.
What is the P/E ratio for Stoke Therapeutics stock?
The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 0 as of March 27, 2026.
Does Stoke Therapeutics stock pay dividends?
No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of March 27, 2026.
When is the next Stoke Therapeutics dividend payment date?
Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Stoke Therapeutics?
Stoke Therapeutics (STOK) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.